Navigation Links
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
Date:7/28/2014

CARLSBAD, Calif., July 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, August 4 at 10:30 a.m. ET / 7:30 a.m. PTWhere:www.isispharm.com How:Live on the Internet. Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, and the therapeutic and commercial potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
2. Amgen Announces Webcast of 2014 Second Quarter Financial Results
3. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
4. Thoratec Schedules Second Quarter Conference Call, Webcast
5. Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
6. Webcast Alert: Heska Announces Second Quarter 2014 Earnings Conference Call Webcast
7. STAAR Surgical Announces Second Quarter 2014 Results Release Date, Conference Call And Webcast
8. Hill-Rom Holdings, Inc. Hosts Fiscal 2014 First Quarter Earnings Conference Call and Webcast
9. ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results
10. Cepheid to Webcast Upcoming Financial Presentation
11. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... JOSE, Calif. , Feb. 21, 2017 Cadence ... that its Cadence ® Tensilica ® Fusion F1 ... ™ MAC IP offering. The licensable IP targets SoCs ... city and industrial applications. M2B leveraged the Fusion F1 DSP ... run value-added applications like voice trigger, audio identification and sensor ...
(Date:2/21/2017)... Research and Markets has announced the addition of the "Liver Cirrhosis ... ... Cirrhosis Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... answers the following questions: What are the key ... positioned in the Global Liver Cirrhosis market? What are ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Rosacea market? ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was ... American Society of Plastic Surgeons. Some patients want to make a change in the ... and improve their breathing ability. The team at usrhinoplasty.org is expanding its ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm ... County, is embarking on a six month charity event aimed at raising local support ... Cancer is one of the deadliest diseases in America; more than 7.5 million people ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... and conference coverage in veterinary medicine, will be launching its first bi-monthly issue ... health and medicine, business and practice management, and One Health. , In ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each February ... History Month (officially African American History Month ). This month-long ... of a diverse race of people, but also the opportunity to examine the ...
(Date:2/21/2017)... California (PRWEB) , ... February 21, 2017 , ... ... world with over 50,000 participants. The connected care demonstration spanned multiple health ... the National Coordinator, roughly 30% of providers have no Health Information Exchange outside ...
Breaking Medicine News(10 mins):